Novartis dials down RNA research

Share this article:

Novartis is scaling down its push to develop RNA therapies. BioCentury reports that the drugmaker plans to “maintain a small group in the field and will look into partnering opportunities” but will “significantly reduce” its internal focus.

According to BioCentury, the drugmaker said RNA treatments look to be a narrow field and that the company expects to lay off some of the 26 employees dedicated to RNA research.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.